Testosterone topical - Novavax

Drug Profile

Testosterone topical - Novavax

Alternative Names: ESP 210

Latest Information Update: 30 Oct 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novavax
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone agonists; Testosterone congener stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Female sexual dysfunction; Hypogonadism

Most Recent Events

  • 23 Jan 2015 Biomarkers information updated
  • 25 Oct 2007 Novavax and Allergan terminate their licensing agreement for testosterone topical lotion
  • 18 Oct 2007 Esprit Pharma has been acquired by Allergan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top